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journal homepage: www.e-asianjournalsurgery.comLETTERS TO THE EDITORThe sum of defined daily doses does not
represent the potency of an antihypertensive
drug regimenDear Editor,
Takanobu Utsumi and colleagues underline the difficulty to
account for medication changes when comparing blood
pressure (BP) before and after adrenalectomy in patients
with primary aldosteronism (PA) [1]. This is a common
concern when assessing the effect of any BP lowering
intervention while the background pharmacological treat-
ment is amenable to changes.
The authors rightly indicate that simply summing the
number of antihypertensive drug classes neglects the dose
of each drug. They propose to add the number of daily-
defined doses (DDD) of each drug to better reflect the
antihypertensive potency of a drug regimen. Three under-
lying assumptions must be questioned: first, that all drugs
prescribed at one DDD have the same antihypertensive
potency; second, that the potency of any drug is propor-
tional to the number of DDD; third, that the potency of
multiple drugs is the sum of their individual potency.
The first assumption is supported by strong evidence in
the context of essential hypertension [2]. However, all drug
classes are not equal in patients with PA. For instance, one
DDD of an aldosterone antagonist is much more effective
than one DDD of an angiotensin converting enzyme inhibitor
in these patients. The second assumption is false, even in
the context of essential hypertension: when the dose of an
antihypertensive drug is doubled, its antihypertensive ef-
fect is only increased by 20% [2]. The third assumption is
again supported by strong evidence in essential hyperten-
sion [2], and I see no reason to think that it is false in pa-
tients with PA.
Let us go back to the example taken in the paper:
epleronone 100 mg + amlodipine 10 mg preoperatively and
cilnidipine 10 mg postoperatively. We must first assume
that 2 DDD of eplerenone have 1.2 times the potency of 1
DDD. Likewise, 2 DDD of amlodipine have 1.2 times the
potency of 1 DDD. Taken together, 2 DDD of eplerenone þ 2Conflict of interest: None.DDD of amlodipine have 2.4 times the potency of 1 DDD of a
single drug. From this preoperative regimen, a single
postoperative drug at one DDD represents a -58% decrease
in antihypertensive potency. This is far from the -75%
decrease in the sum of DDD.
By contrast, we always use the number of drug classes as
a proxy for the antihypertensive potency of a regimen [3-
5]. Going from a 2 drugs regimen to a 1 drug regimen, as
in the example from the paper, represents a -50% decrease
in the number of antihypertensive drug classes. While
simpler, this approximation (-50%) is also closer to the real
drop in antihypertensive potency (-58%) than the decrease
in the sum of DDD (-75%).
To conclude, Takanobu Utsumi and colleagues are right:
the number of drug classes is a biased estimate of the po-
tency of an antihypertensive regimen. However, it is less so
than the total number of DDD, because the impact of
combining drug classes largely prevails over increasing their
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http://dx.doi.org/10.1016/j.asjsur.2015.02.001The defined daily dose is a simple tool to assess
total drug consumption as a measurement unitWe previously reported that the defined daily dose (DDD) is
a useful tool to assess the total consumption of antihyper-
tensive drugs in patients with primary aldosteronism (PA).
Thus, DDD can be used as a substitute for the number of
antihypertensive drug classes.1 Oliver Steichen2 agreed that
the number of antihypertensive drug classes cannot accu-
rately reflect the total consumption of antihypertensive
drugs in PA patients.
Furthermore, he politely indicated some limitations in
our previous study.2 He assumed that all antihyperten-
sive drugs at one DDD do not necessarily have the same
potency, because one DDD of an aldosterone antagonist
is much more effective than one DDD of the other
classes of antihypertensive drugs in PA patients. How-
ever, even aldosterone antagonists, such as spi-
ronolactone and eplerenone, are not equally effective in
each PA patient because of different background fac-
tors. Some investigators reported different responses to
spironolactone in each PA patient, which was suggested
to be a primary drug in postoperative hypertension
cure.3,4 Proye et al4 suggested that PA patients who did
not respond to spironolactone had coexisting essential
hypertension. Prolonged hyperaldosteronism induces
detrimental and irreversible effects on the cardiovas-
cular system, which could result in resistant hyperten-
sion despite normalizing plasma aldosterone levels after
surgery.5
Oliver Steichen2 presented a calculation example for the
antihypertensive potency in his own way. However, his
calculation method neglects each patient’s different back-
ground factors. Patients with PA who had accumulated
vascular damage, such as longer duration of hypertension
and older age, are thought to be considerably influenced by
coexisting essential hypertension.
We emphasize again that the DDD is a simple tool to
assess and compare drug consumption, not to be confused
with the therapeutic dose or with the dose actually pre-
scribed by a physician for an individual patient. The pri-mary goal of our previous study was to assess post-
operative changes in antihypertensive drug consumption,
not antihypertensive drug potency.1 We did not assess the
antihypertensive potency of a drug regimen in our study.1
If clinicians would like to assess the antihypertensive po-
tency of a drug regimen, a prospective study that includes
preoperative and postoperative blood pressure (BP) data
for each patient should be conducted after adjustment of
each used drug and background factor.
Oliver Steichen is right: the DDD might not be able to
reflect the antihypertensive potency of a drug regimen
completely. A prospective study that includes complete
analysis of BP data after adjustment of each used drug and
background factor will be needed to assess the potency of
antihypertensive drugs, because the degree of coexisting
essential hypertension differs in each PA patient. At pre-
sent, the DDD is an irreplaceable tool to assess and
compare total drug consumption as a measurement unit in
a person.
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